CORONAVIRUS

UK authorizes Merck antiviral pill, 1st shown to treat COVID

Nov 4, 2021, 8:48 AM
(Merck via CNN)...
(Merck via CNN)
(Merck via CNN)

LONDON (AP) — Britain granted conditional authorization on Thursday to the first pill shown to successfully treat COVID-19 so far. It also is the first country to OK the treatment from drugmaker Merck, although it wasn’t immediately clear how quickly the pill would be available.

The pill was licensed for adults 18 and older who have tested positive for COVID-19 and have at least one risk factor for developing severe disease, such as obesity or heart disease. Patients with mild-to-moderate COVID-19 would take four pills of the drug, known molnupiravir, twice a day for five days.

An antiviral pill that reduces symptoms and speeds recovery could prove groundbreaking, easing caseloads on hospitals and helping to curb outbreaks in poorer countries with fragile health systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations.

Molnupiravir is also pending review with regulators in the U.S., the European Union and elsewhere. The U.S. Food and Drug Administration announced last month it would convene a panel of independent experts to scrutinize the pill’s safety and effectiveness in late November.

Initial supplies will be limited. Merck has said it can produce 10 million treatment courses through the end of the year, but much of that supply has already been purchased by governments worldwide.

In October, U.K. officials announced they secured 480,000 courses of molnupiravir and expected thousands of vulnerable Britons to have access to the treatment this winter via a national study.

“Today is a historic day for our country, as the U.K. is now the first country in the world to approve an antiviral that can be taken at home for COVID-19,” British health secretary Sajid Javid said.

“We are working at pace across the government and with the NHS to set out plans to deploy molnupiravir to patients through a national study as soon as possible,” he said in a statement, referring to the U.K.’s National Health Service. Doctors said the treatment would be particularly significant for people who don’t respond well to vaccination.

Merck and partner Ridgeback Biotherapeutic have requested clearance for the drug with regulators around the world for adults with early cases of COVID-19 who are at risk for severe disease or hospitalization. That’s roughly the same group targeted for treatment with infused COVID-19 antibody drugs, the standard of care in many countries for patients who don’t yet require hospitalization.

Merck announced preliminary results in September showing its drug cut hospitalizations and deaths by half among patients with early COVID-19 symptoms. The results haven’t yet been peer reviewed or published in a scientific journal.

The company also didn’t disclose details on molnupiravir’s side effects, except to say that rates of those problems were similar between people who got the drug and those who received dummy pills.

The drug targets an enzyme the coronavirus uses to reproduce itself, inserting errors into its genetic code that slow its ability to spread and take over human cells. That genetic activity has led some independent experts to question whether the drug could potentially cause mutations leading to birth defects or tumors.

Britain’s Medicines and Healthcare products Regulatory Agency said molnupiravir’s ability to interact with DNA and cause mutations had been studied “extensively” and that it wasn’t found to pose a risk to humans.

“Studies in rats showed that (molnupiravir) may cause harmful effects to the unborn offspring, although this was at doses which were higher than those that will be given to humans, and these effects were not observed in other animals,” the agency said in an email.

In company trials, both men and women were instructed to either use contraception or abstain from sex. Pregnant women were excluded from the study. Merck has stated that the drug is safe when used as directed.

Molnupiravir was initially studied as a potential flu therapy with funding from the U.S. government. Last year, researchers at Emory University decided to repurpose the drug as a potential COVID-19 treatment. They then licensed the drug to Ridgeback and partner Merck.

Last week, Merck agreed to allow other drugmakers to make its COVID-19 pill, in a move aimed at helping millions of people in poorer countries get access. The Medicines Patent Pool, a U.N.-backed group, said Merck will not receive royalties under the agreement for as long as the World Health Organization deems COVID-19 to be a global emergency.

But the deal was criticized by some activists for excluding many middle-income countries capable of making millions of treatments, including Brazil and China.

Still, experts commended Merck for agreeing to widely share its formula and promising to help any companies who need technological help in making their drug — something no coronavirus vaccine producers have agreed to.

“Unlike the grotesquely unequal distribution of COVID-19 vaccines, the poorest countries will not have to wait at the back of the queue for molnupiravir,” said Dr. Mohga Kamal-Yanni, a senior health adviser to the People’s Vaccine Alliance. Fewer than 1% of the world’s COVID-19 vaccines have gone to poor countries and experts hope easier-to-dispense treatments will help them curb the pandemic.

Merck previously announced licensing deals with several Indian makers of generic drugs to manufacture lower-cost versions of molnupiravir for developing countries.

The U.S. has agreed to pay roughly $700 per course of the drug for about 1.7 million treatments. Merck says it plans to use a tiered pricing strategy for developing countries. A review by Harvard University and King’s College London estimated the drug costs about $18 to make each 40-pill course of treatment.

While other treatments have been cleared to treat COVID-19, including steroids and monoclonal antibodies, those are administered by injection or infusion and are mostly used in hospitals and other health care facilities.

___

Matthew Perrone reported from Washington.

___

Follow AP’s pandemic coverage at https://apnews.com/hub/coronavirus-pandemic

KSL 5 TV Live

Top Stories

Coronavirus

Representative Tricia Derges (Credit: Missouri House of Representatives)...
Associated Press

Missouri lawmaker resigns from House after fraud conviction for selling Covid treatments

A Missouri GOP legislator has resigned after being convicted of falsely claiming she was giving patients stem cell treatments for COVID-19.
2 days ago
FILE PHOTO (Photo by Jacob King - WPA Pool/Getty Images)...
MIKE STOBBE, AP Medical Writer

Moderna COVID-19 shots now an option for older kids in US

There is now a second COVID-19 option for kids ages 6 to 17 in the U.S.
11 days ago
Pfizer says it's COVID-19 vaccine is 100% effective in kids 12 to 15. (Justin Tallis-Pool/Getty Ima...
Jen Christensen, CNN

What are the COVID-19 vaccine side effects in young kids? Experts seek to ease parents’ concerns

Experts look at what side effects to expect from the COVID vaccine for children six months and older.
13 days ago
The Nurse Crisis and Patent Risk....
Debbie Worthen

Utah registered nurses are leaving the field, creating the ‘perfect storm’

"Without nurses, we can't have hospitals." Utah nurses are overworked and underpaid. Some say it's put people at risk.
14 days ago
Four-year-old Viola Fairfax-Panza Getting her COVID-19 vaccination, held by her mother Keke Fairfax...
Jed Boal

Salt Lake Co. distributes COVID vaccines for children 6-months and older

Salt Lake County begins COVID-19 vaccinations for children 6 months and older.
14 days ago
U.S. President Joe Biden speaks about Covid-19 vaccines for children, in the Roosevelt Room of the ...
ZEKE MILLER and JOSH BOAK, Associated Press

Biden visits clinic, celebrates COVID shots for kids under 5

President Joe Biden is celebrating that virtually all Americans can now get a COVID-19 shot after the authorization of vaccines for kids under 5 over the weekend.
14 days ago

Sponsored Articles

hand holding 3d rendering mobile connect with security camera for security solutions...
Les Olson

Wondering what security solutions are right for you? Find out more about how to protect your surroundings

Physical security helps everyone. Keep your employees, clients, and customers safe with security solutions that protect your workplace.
Many rattan pendant lights, hay hang from the ceiling.Traditional and simple lighting....
Lighting Design

The Best Ways to Style Rattan Pendant Lighting in Your Home

Rattan pendant lights create a rustic and breezy feel, and are an easy way to incorporate this hot trend into your home decor.
Earth day 2022...
1-800-GOT-JUNK?

How Are You Celebrating Earth Day 2022? | 4 Simple Ways to Celebrate Earth Day and Protect the Environment

Earth Day is a great time to reflect on how we can be more environmentally conscious. Here are some tips for celebrating Earth Day.
Get Money Online...

More Ways to Get Money Online Right Now in Your Spare Time

Here are 4 easy ways that you can get more money online if you have some free time and want to make a little extra on the side.
Lighting trends 2022...

Lighting Trends 2022 | 5 Beautiful Home Lighting Trends You Can Expect to See this Year and Beyond

This is where you can see the latest lighting trends for 2022 straight from the Lightovation Show at the Dallas World Trade Center.
What Can't You Throw Away in the Trash...

What Can’t You Throw Away in the Trash? | 5 Things You Shouldn’t Throw in to Your Trash Can

What can't you throw away in the trash? Believe it or not, there are actually many items that shouldn't be thrown straight into the trash.
UK authorizes Merck antiviral pill, 1st shown to treat COVID